CNS Pharmaceuticals’ (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date
CNS Pharmaceuticals, Inc. today announced it has achieved enrollment of 229 of the expected 243 patients in the ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer.
